Clinical trial · Interventional
BCX-1777 in Treating Patients With Refractory Cancer
Phase I Pharmacology Study Of Oral And Intravenous BCX-1777 In Patients With Refractory T-Cell And Non-T-Cell Malignancies
NCT00073944CI-TRIAL-00010470completedPhase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: BCX-1777 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: Phase I trial to study the effectiveness of BCX-1777 in treating patients who have refractory cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| forodesine hydrochloride | Drug | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS:
* Histologically confirmed diagnosis of 1 of the following:
* Hematologic malignancy that is refractory to at least 1 prior curative treatment
* Non-hematologic tumor that is refractory to at least 2 prior therapies, with or without measurable disease, including the following:
* Gastrointestinal adenocarcinoma of 1 of the following sites:
* Pancreatic
* Biliary
* Gastric
* Colorectal
* Esophageal
* Melanoma
* Ovarian cancer
* Astrocytoma brain tumor
* Not immediately eligible for any other treatment that would be potentially curative or life-prolonging, in the opinion of the investigator
* Patients who may be candidates for future bone marrow transplantation are eligible
* No brain metastases (other than astrocytomas)
* No clinically significant pleural effusion
* No complete tumor obstruction (e.g., bronchus, ureter, or bowel)
PATIENT CHARACTERISTICS:
Age
* 18 and over
Performance status
* ECOG 0-2 OR
* Karnofsky 50-100%
Life expectancy
* Not specified
Hematopoietic
* WBC at least 3,500/mm\^3
* Absolute neutrophil count at least 1,500/mm\^3
* Platelet count greater than 50,000/mm\^3
* Hematocrit stable without the need for transfusion (epoetin alfa support allowed)
Hepatic
* Bilirubin less than 1.5 times upper limit of normal (ULN) (unless due to Gilbert's syndrome)
* SGOT and SGPT less than 2 times ULN
* No active hepatitis B or C
Renal
* Creatinine clearance at least 50 mL/min
Cardiovascular
* No American Heart Association class III or IV cardiac disease
Other
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception
* HIV negative
* No active systemic infection requiring IV antibiotics
PRIOR CONCURRENT THERAPY:
Biologic therapy
* Not specified
Chemotherapy
* Not specified
Endocrine therapy
* Concurrent corticosteroids allowed provided the patient is on a stable regimen
Radiotherapy
* Not specified
Surgery
* Not specified
Other
* Recovered from prior therapy
* No grade 2-4 toxicity
* More than 3 weeks since prior antineoplastic and/or investigational therapy
* No other concurrent systemic antineoplastic or investigational therapyReferences
Publications (0)
Data not yet available
No reference posted for this study.